EWA
TVTX icon

Evolution Wealth Advisors’s Travere Therapeutics TVTX Stock Holding History

Evolution Wealth Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-212
Closed -$5K – 593
2021
Q3 		$5K Sell
212
-239
-53% -$4.39K ﹤0.01% 525
2021
Q2 		$7K Sell
451
-129
-22% -$2.54K ﹤0.01% 465
2021
Q1 		$14K Hold
580
– – ﹤0.01% 364
2020
Q4 		$16K Buy
+580
New +$13.5K ﹤0.01% 294

Other funds holding TVTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Evolution Wealth Advisors's TVTX Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Travere Therapeutics (TVTX) in Q4 2021, closing a stake of 212 shares — an estimated $5K sold.

Evolution Wealth Advisors first reported a position in TVTX in Q4 2020 and held it in 4 quarters. The position peaked at $16K in Q4 2020. 169 funds tracked by Wall St. Rank hold TVTX as of Q4 2021.

  • Evolution Wealth Advisors reported no remaining Travere Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Evolution Wealth Advisors sold 212 Travere Therapeutics shares in Q4 2021, an estimated $5K.
  • Evolution Wealth Advisors first reported a position in Travere Therapeutics in Q4 2020 and held it in 4 quarters.
  • Evolution Wealth Advisors's Travere Therapeutics position peaked at $16K in Q4 2020.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.